(OTC BB-NASDAQ: VPRO) OVERVIEW
Viropro Inc. (“Viropro”) operates through Viropro International Inc., a Canadian company with its Head Office in Montreal. Viropro International Inc. is specialized in the technology transfer for industrial production of affordable biological therapeutic products whose licenses have expired. The principal objective is to support pharmaceutical companies in South America, Asia, Africa and Eastern Europe, by offering them the opportunity to locally produce and commercialize therapeutic products of industrial quality at an affordable price. Viropro enables emerging markets with unmet medical needs to gain access to therapeutic biological products for the treatment of various diseases such as cancer, diabetes, chronic hepatitis, multiple sclerosis, and rheumatoid arthritis. The innovative business strategy of Viropro International Inc. is based on the acquisition of exclusive products and technological rights/licenses/patents, simultaneously with the development of key partnerships with pre-eminent players on a national and international scale. Viropro International Inc. has already concluded agreements with Immuno Japan Inc. (Worldwide exclusive rights to expression systems designed to increase the production of biotherapeutic products; access to a series of biological products), the Biotechnological Research Institute of the National Council of Canada (Montreal: Worldwide exclusive rights to the use of patented expression systems for the production of human Interferon beta and monoclonal antibodies; scale-up and production processes), and the Laboratory of Veterinary and Food Biotechnology of the University of Montreal (development of validation runs, clinical material and commercialization lots in a cGMP environment). Beyond its extensive network of expertise and scientific partnerships, Viropro relies on the wide knowledge of its management team led by Dr. Jean-Marie Dupuy, a leading, world-recognized immunologist. Dr. Dupuy has worked in France, the United States and Canada, in internationally renowned pharmaceutical and medical enterprises.
RECENT KEY ANNOUNCEMENTS
; APRIL 2006 ; Signing of a new exclusive license agreement with the Japanese firm Immuno Japan Inc., further strengthening the agreement signed between the parties in November 2004. This license agreement grants Viropro exclusive rights for the marketing on a world scale (excluding Japan) of newly licensed biological therapeutic products. ; Signing of a collaborative agreement with the French consulting firm Parteurop recognized worldwide for its expertise in the biopharmaceutical field and for its impressive network of private and institutional partnerships. ; JUNE 2006 – Signing of an agreement in Tunisia with the pharmaceutical company BioChallenge. This Memorandum of Understanding (MOU) signed between parties fills an important need for Tunisia and other African countries since it will be the first implementation of a manufacturing facility for the production of industrial biological therapeutic products in that part of the world. It will allow greater drug accessibility to the population for treating unmet medical needs. ; SEPTEMBER 2006 – Signing of a collaborative agreement with the Laboratory of Veterinary and Food Biotechnology (LVFB) of the Faculty of Veterinary of University of Montreal, aiming at developing therapeutic products in an ultramodern infrastructure that conforms to Good Manufacturing Practices (GMP). ; OCTOBER 2006 ; Viropro increases its visibility by signing with Echoes Financial Network Inc, an ?investor relations and related communications? firm. ; Signature of an agreement with the Biotechnology Research Institute (?BRI?) for the acquisition of worldwide exclusive rights for the production of a recombinant human Interferon beta (?rH INF beta?). ; NOVEMBER 2006 ; Appointment of Mr. Gino Di Iorio as Chief Financial Officer.
; NOVEMBER 2006 (continued) ; Signature of a US$ 42 million collaborative agreement with BioChallenge S.A., for the development and the technology transfer of 4 biotherapeutic products. BioChallenge, a Tunisian private pharmaceutical company, will manufacture locally and commercialize these high quality low cost biopharmaceuticals. Viropro would receive US$ 42 Million as licensing fees, development and technology transfer costs, and royalties on future sales. BioChallenge will commercialize these biogeneric products at a much lower price to more than 700 million people who do not have access to specific biological products for the treatment of diseases such as anaemia, multiple sclerosis, neutropenia, chronic hepatitis B and chronic hepatitis C. Revenues for BioChallenge would arise in 2008 with a pre-marketing of finished goods purchased from Contract Manufacturing Organizations (?CMO’s?). Plant construction would start in the fall of 2007 and first revenues coming from that plant would arise at the end of 2009.
TYPE OF COMPANY SCOPE Public Company (OTC BB – NASDAQ : VPRO) Biotechnology, biological therapeutic proteins
TEAM STRATEGIC PARTNERSHIPS ; Dr. Jean-Marie Dupuy, President and CEO ; Immuno Japan Inc. ; Gino Di Iorio, C.A., CFO ; The Biotechnological Research Institute of the National ; Prosper Azoulay, VP Operations Research Council of Canada, Montreal ; Andre Bedard, Business Development and ; Laboratory of Veterinary and Food Biotechnology of International Partnerships the University of Montreal ; Patrick Daoust, Director, Bio-Therapeutics ; Parteurop, France ; Patrick Benoist, Project Director ; Dr. Maximilien Arella, Chairman, Scientific Advisory Committee
YEAR ESTABLISHED COMPANY SIZE 2003 10 people MARKET RANGE REVENUE South America, Europe, Asia, Africa Within next quarters
INVESTOR RELATIONS CONTACT US DOMINIC SICOTTE VIROPRO INC. Echoes Financial Network Inc 8515, Place Devonshire, Suite 207 514-842-9551 / 866-633-9551 Montreal (Quebec) Canada H4P 2K1 email@example.com Tel: 514.731.VPRO (8776) www.viropro.com STOCK INFORMATION
Ticker: VPRO Exchange: OTCBB Price (10/27/06): $ 0.50 Market cap: $16.4 Million Shares Outstanding: (approximately) 32.7 Million 52-week high: $ 1.42 52-week low: $ 0.20 Fiscal year end: November
NOTE & DISCLOSURES This document contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investor should consult the Company’s quarterly and annual filings with the U.S. security commission for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.